← Evidence map

ArticleActa pharmaceutica Sinica. B2026

Dual-driven by regulatory science and policy reconstruction: Traditional Chinese medicine (TCM) new drugs accelerate development-A critical review of highlights in registration and regulation of TCM and natural medicine new drugs in China (2021-2025).

Junning Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Dual-driven by regulatory science and policy reconstruction: Traditional Chinese medicine (TCM) new drugs accelerate development-A critical review of highlights in registration and regulation of TCM and natural medicine new drugs in China (2021-2025). | Socratic